Masako Narita

Aug 7, 2024 | nature.com | Haoran Zhu |Masako Narita |Sarah Gough |Lars Zender |Sarah Aitken |Matthew Hoare | +2 more

AbstractOncogenic RAS-induced senescence (OIS) is an autonomous tumour suppressor mechanism associated with premalignancy1,2. Achieving this phenotype typically requires a high level of oncogenic stress, yet the phenotype provoked by lower oncogenic dosage remains unclear. Here we develop oncogenic RAS dose-escalation models in vitro and in vivo, revealing a RAS dose-driven non-linear continuum of downstream phenotypes.